Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: A prospective, randomized controlled phase III trial

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 99-105

  Westin, Jason R ^a   Thompson, Michael A ^b   Cataldo, Vince D ^c   Fayad, Luis E ^a   Fowler, Nathan ^a   Fanale, Michelle A ^a   Neelapu, Saatva ^a   Samaniego, Felipe ^a   Romaguera, Jorge ^a   Shah, Jatin ^a   McLaughlin, Peter ^a   Pro, Barbara ^d   Kwak, Larry W ^a   Sanjorjo, Perpetua ^a   Murphy, William A ^a   Jimenez, Camillo ^a   Toth, Bela ^a   Dong, Wenli ^a   Hagemeister, Fredrick B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ProHealth Care Regional Cancer Center   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Bone density; Bone loss; Calcium; Lymphoma; Newly diagnosed; Osteopenia; Osteoporosis; Vitamin D; Zoledronic acid

Indexed keywords

ALKYLATING AGENT; BIOLOGICAL MARKER; CALCIUM; CORTICOSTEROID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DEMINERALIZATION; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY INTERVENTION; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR GROWTH; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877325041     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.002     Document Type: Article

References (50)

1. J. Pfeilschifter, I.J. Diel Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 2000 1570 1593 (Pubitemid 30205404)
2. J. Klaus, G. Armbrecht, M. Steinkamp High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease Gut 51 2002 654 658 (Pubitemid 35216851)
3. T.P. Van Staa, H.G. Leufkens, L. Abenhaim Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 2000 993 1000 (Pubitemid 30350061)
4. T.P. Van Staa, H.G. Leufkens, L. Abenhaim Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology (Oxford) 39 2000 1383 1389 (Pubitemid 32045866)
5. K.G. Saag, R. Koehnke, J.R. Caldwell Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events Am J Med 96 1994 115 123 (Pubitemid 24070529)
6. R. Eastell, D.M. Reid, J. Compston A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update J Intern Med 244 1998 271 292 (Pubitemid 28473991)
7. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis Arthritis Rheum 44 2001 1496 1503
8. R.A. Adler, M.C. Hochberg Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs Arch Intern Med 163 2003 2619 2624 (Pubitemid 37464420)
9. R.N. Richards Side effects of short-term oral corticosteroids J Cutan Med Surg 12 2008 77 81
10. J. Bines, D.M. Oleske, M.A. Cobleigh Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol 14 1996 1718 1729 (Pubitemid 26134232)
11. J.M. Campion, M.J. Maricic Osteoporosis in men Am Fam Physician 67 2003 1521 1526 (Pubitemid 36427944)
12. C.E. Kiserud, A. Fosså, T. Bjøro Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy Br J Cancer 100 2009 455 463
13. D.M. Preston, J.I. Torréns, P. Harding Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss Prostate Cancer Prostatic Dis 5 2002 304 310 (Pubitemid 36124442)
14. M.C. Hochberg, P.D. Ross, D. Black Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis Fracture Intervention Trial Research Group Arthritis Rheum 42 1999 1246 1254 (Pubitemid 29268962)
15. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines In Oncology: Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site Accessed: November 29, 2012
16. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis 2010 National Osteoporosis Foundation Washington, DC
17. E.S. Leib, E.M. Lewiecki, N. Binkley Official positions of the International Society for Clinical Densitometry J Clin Densitom 7 2004 1 6
18. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract; 16(suppl 3):1-37.
19. U.S. Preventive Services Task Force Screening for osteoporosis: U.S. preventive services task force recommendation statement Ann Intern Med 154 2011 356 364
20. M.A. Thompson, A. Huen, R. Toth Osteopenia and osteoporosis in untreated non-Hodgkin's lymphoma patients: an important and potentially treatable survivorship issue in lymphoma J Clin Oncol 25 suppl 2007 9055
21. A. Lipton, J.R. Berenson Bisphosphonate treatment of lytic bone metastases Drugs Aging 14 1999 241 246 (Pubitemid 29195342)
22. G.R. Mundy, R. Wilkinson, D.A. Heath Comparative study of available medical therapy for hypercalcemia of malignancy Am J Med 74 1983 421 432 (Pubitemid 13157644)
23. I. Elomaa, C. Blomqvist, P. Gröhn Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases Lancet 1 1983 146 149 (Pubitemid 13224094)
24. J.R. Berenson, A. Lichtenstein, L. Porter Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma Myeloma Aredia Study Group N Engl J Med 334 1996 488 493 (Pubitemid 26067736)
25. G.N. Hortobagyi, R.L. Theriault, L. Porter Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1996 1785 1791 (Pubitemid 26412396)
26. P.F. Conte, J. Latreille, L. Mauriac Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial The Aredia Multinational Cooperative Group J Clin Oncol 14 1996 2552 2559 (Pubitemid 26300123)
27. R. Schenk, P. Eggli, H. Fleisch Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat Calcif Tissue Int 38 1986 342 349 (Pubitemid 16081453)
28. P.M. Boonekamp, C.W. Löwik, L.J. van der Wee-Pals Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group Bone Miner 2 1987 29 42 (Pubitemid 17034731)
29. A.M. Flanagan, T.J. Chambers Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone Calcif Tissue Int 49 1991 407 415
30. P.H. Reitsma, S.L. Teitelbaum, O.L. Bijvoet Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro J Clin Invest 70 1982 927 933 (Pubitemid 13254916)
31. P.M. Boonekamp, L.J. van der Wee-Pals, M.M. van Wijk-van Lennep Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix Bone Miner 1 1986 27 39 (Pubitemid 16018095)
32. D.E. Hughes, B.R. MacDonald, R.G. Russell Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow J Clin Invest 83 1989 1930 1935 (Pubitemid 19148862)
33. K. Müller, I. Wiesenberg, K. Jaeggi Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat Arzneimittelforschung 48 1998 81 86 (Pubitemid 28048610)
34. N. Binkley, D. Kimmel, J. Bruner Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys J Bone Miner Res 13 1998 1775 1782 (Pubitemid 28492009)
35. S.H. Kim, S.K. Lim, J.S. Hahn Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy Am J Med 116 2004 524 528 (Pubitemid 38452643)
36. J.R. Green, K. Muller, K.A. Jaeggi Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 1994 745 751 (Pubitemid 24130477)
37. A.O. Hoff, B.B. Toth, K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826 836 (Pubitemid 351768801)
38. M.F. Holick Vitamin D deficiency N Engl J Med 357 2007 266 281
39. J.A. Kanis World Health Organization Scientific Group Assessment of osteoporosis at the primary health-care level Technical report 2008 WHO Collaborating Centre, University of Sheffield, UK
40. R. Dresner-Pollak, R.A. Parker, M. Poku Biochemical markers of bone turnover reflect femoral bone loss in elderly women Calcif Tissue Int 59 1996 328 333 (Pubitemid 26367078)
41. S.L. Greenspan, N.M. Resnick, R.A. Parker Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial J Clin Endocrinol Metab 90 2005 2762 2767 (Pubitemid 40686321)
42. Anargyrou K, et al. First-line chemotherapy leads to high bone turnover and reduced bone mass in patients with non-Hodgkin's lymphoma (NHL). Presented at the 51st annual American Society of Hematology meeting. New Orleans: December 5-8. Abstract 114:1951.
43. M.E. Cabanillas, H. Lu, S. Fang Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures Leuk Lymphoma 48 2007 1514 1521 (Pubitemid 47272801)
44. A.C. Looker, L.J. Melton, T.B. Harris Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III J Bone Miner Res 25 2010 64 71
45. J.L. Kelly, J.W. Friedberg, L.M. Calvi Vitamin D and non-Hodgkin lymphoma risk in adults: a review Cancer Invest 27 2009 942 951
46. D.M. Freedman, A.C. Looker, S.C. Chang Prospective study of serum vitamin D and cancer mortality in the United States J Natl Cancer Inst 99 2007 1594 1602
47. D.M. Black, P.D. Delmas, R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809 1822 (Pubitemid 46698462)
48. M.A. Dimopoulos, E. Kastritis, A. Anagnostopoulos Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid Haematologica 91 2006 968 971 (Pubitemid 44023154)
49. J.D. Isaacs, L. Shidiak, I.A. Harris Femoral insufficiency fractures associated with prolonged bisphosphonate therapy Clin Orthop Relat Res 468 2010 3384 3392
50. A national action plan for cancer survivorship: advancing public health strategies 2004 Centers for Disease Control and Prevention and Lance Armstrong Foundation Washington D.C. http://www.cdc.gov/cancer/survivorship/pdf/plan.pdf Accessed: November 30, 2012